Yi Lin, MD, PhD

Articles

Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

October 19th 2023

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

September 7th 2023

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1

September 7th 2023

Yi Lin, MD, PhD, the predictive value of baseline characteristics in relation to sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

August 17th 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

April 21st 2022

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

January 20th 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Dr. Lin on CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

January 13th 2021

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

Dr. Lin on Patient Characteristics From the CRB-401 Study of Ide-Cel in Myeloma

January 5th 2021

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

Dr. Lin on the Promise of Cilta-Cel and Ide-Cel in Myeloma

December 21st 2020

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

Dr. Lin on Updated Results of the CRB-401 Trial in Relapsed/Refractory Multiple Myeloma

December 8th 2020

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.